2025 marked an exciting phase for covalent drugs, with the field doubling down on de-risked assets and tackling high-value targets in oncology, immunology, and beyond. With MOMA Therapeutics having recently dosed their first patient with a covalent Werner helicase inhibitor, and Novartis partnering with covalent pioneer Matchpoint Therapeutics in a $60 million deal, it was clear that the therapeutic potential of covalency was growing.

The 3rd Covalent Drug Discovery & Development Summit returned as the premier industry forum for experts to accelerate the discovery, translation and development of covalent drugs, driving the next wave of first- and best-in-class therapeutics against previously undruggable targets.

Uniting covalent drug leaders from the likes of Vividion Therapeutics, Pfizer, Revolution Medicines and Frontier Medicines, this three day deep-dive forum will focus on:

• Optimizing warhead selectivity, reactivity and durability to ensure the development of tolerable, potent covalent therapies
• Targeting non-cysteine residues and hard-to-drug proteins including transcription factors to expand the druggable proteome
• Elucidating PK/PD relationships and understanding ADME and target engagement to inform dosing and streamline clinical development
• Innovating advanced screening technologies and lead optimization strategies to rationally triage hits and progress covalent candidates efficiently